P012 Clinching the Diagnosis: Dermpath, CPC, Testing and Beyond
DESCRIPTION
The majority of dermatological conditions can be diagnosed through an office visit, often with the support of a biopsy interpreted by a dermatopathologist. Correlating clinical findings with pathological results (CPC) is crucial for a definitive diagnosis. In certain cases, more investigative history taking or further tests may be necessary, such as immunofluorescence or molecular studies like PCR, next-generation sequencing, or FISH. This session will concentrate on the diagnostic aspects of dermatological conditions that extend beyond the clinical examination of the patient, including case examples.
LEARNING OBJECTIVES
List examples of molecular studies that can be helpful in diagnosing dermatologic conditions.
Discuss the impact of molecular studies on the diagnosis and classification of melanoma and atypical melanocytic/Spitzoid neoplasms.
Identify situations in which PCR testing can assist in the diagnosis of dermatologic conditions
SCHEDULE
1:00 PM
Introduction
Jacqueline M. Junkins-Hopkins, MD, FAAD
1:02 PM
Molecular techniques helpful in dermatology with selective demonstrative cases
Allen Gordon Strickler, MD, PhD, MPH, FAAD
1:30 PM
Questions and Answers
Allen Gordon Strickler, MD, PhD, MPH, FAAD
1:35 PM
Case presentations
Alina G. Bridges, DO, FAAD
1:55 PM
Questions and Answers
Alina G. Bridges, DO, FAAD
2:00 PM
Case presentations
Shadi Khalil, MD, PhD, FAAD
2:20 PM
Questions and Answers
Shadi Khalil, MD, PhD, FAAD
2:25 PM
Case Presentations
Alejandro Gru, MD
2:45 PM
Questions and Answers
Alejandro Gru, MD
2:50 PM
Quick tips and conclusions
Jacqueline M. Junkins-Hopkins, MD, FAAD
DIRECTOR
Jacqueline M. Junkins-Hopkins, MD, FAAD
Geisinger Medical Center
SPEAKERS
Alina G. Bridges, DO, FAAD
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Alejandro Gru, MD
Shadi Khalil, MD, PhD, FAAD
Allen Gordon Strickler, MD, PhD, MPH, FAAD
Geisinger Medical Center
HANDOUTS
DISCLOSURES
Alina G. Bridges, DO, FAAD
No financial relationships exist with ineligible companies.
Alejandro Gru, MD
Blueprint Medicines – Advisory Board(Fees); Dren Bio – Consultant (1099 relationship)(Fees); Innate Pharma, S.A. – Investigator(Honoraria);
Jacqueline M. Junkins-Hopkins, MD, FAAD
No financial relationships exist with ineligible companies.
Shadi Khalil, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Allen Gordon Strickler, MD, PhD, MPH, FAAD
No financial relationships exist with ineligible companies.